CAS: 192441-08-0; 6-((4-Bromothiophen-2-yl)Methoxy)-9H-Purin-2-Amine

该化合物是一个化学化合物,主要因其在医学化学领域的应用而引起注意,特别是作为一种潜在的治疗剂,其特点是独特的分子结构,其中包括有助于其生物活动的特定功能组别,Lomeguatrib作为某些酶的选择性抑制剂,可在各种生物化学途径中发挥关键作用,这种选择性对于治疗癌症等病症的潜在用途具有重要意义,因为肿瘤的生长和进化会受到酶活动调节的影响.该化合物的药理动力特性,包括吸收,分布,新陈代谢和排泄物,对于确定其临床环境中的功效和安全特征至关重要.此外,正在进行的研究侧重于了解其行动机制并优化其治疗潜力.与许多实验性化合物一样,必须进一步研究,以充分阐明其在医学中的特性和应用.

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号79757-77-0 (4-溴-2-噻吩基)甲醇 | CAS号34798-95-3 2-amino-N,N,N-t... | CAS号18791-75-8 4-溴-2-噻吩甲醛

合成工艺路线路线简述

    📜4-溴-2-噻吩甲醛置于sodium Tetrahydroborate,Sodium Hydride,二甲基亚砜体系中,用 异丙醇 用作溶剂,化学反应 3.0H,反应生成罗米鲁曲
    参考文献:Monosaccharide-Linked Inhibitors Of O6-Methylguanine-Dna Methyltransferase (Mgmt): Synthesis,Molecular Modeling,And Structure−activity Relationships
    标题:Monosaccharide-Linked Inhibitors Of O6-Methylguanine-Dna Methyltransferase (Mgmt): Synthesis,Molecular Modeling,And Structure−activity Relationships
    摘要:A Series Of Potential Inhibitors Of The Human Dna Repair Protein O-6-Methylguanine-Dna Methyltransferase (Mgmt) Were Synthesized,Characterized In Detail By NMR,And Tested For Their Ability To Deplete Mgmt Activity In Vitro. The New Compounds,Omega-[o-6-R-Guan-9-Yl]-(Ch2)(N)-Beta-D-Glucosides With R = Benzyl Or 4-Bromothenyl And Omega = N = 2,4,... 12,Were Compared With The Established Inhibitors O-6-Benzylguanine (O-6-Bg),8-Aza-O-6-Benzylguanine (8-Aza-Bg),And O-6-(4-Bromothenyl)Guanine (4-Btg),Which Exhibit In An In Vitro Assay Ic50 Values Of 0.62,0.038,And 0.009 Mum,Respectively. Potential Advantages Of The Glucosides Are Improved Water Solubility And Selective Uptake In Tumor Cells. The 4-Btg Glucosides With N = 2,4,6 Show Moderate Inhibition With An Ic50 Of Ca. 0.5 Mum,While Glucosides Derived From Bg And 8-Aza-Bg Showed Significantly Poorer Inhibition Compared To The Parent Compounds. The 4-Btg Glucosides With N = 8,10,12 Were Effective Inhibitors With Ic50 Values Of Ca. 0.03 Mum. To Understand This Behavior,Extensive Molecular Modeling Studies Were Performed Using The Published Crystal Structure Of Mgmt (Pdb Entry: 1Qnt). The Inhibitor Molecules Were Docked Into The Bg Binding Pocket,And Molecular Dynamics Simulations With Explicit Water Molecules Were Carried Out. Stabilization Energies For The Interactions Of Specific Regions Of The Inhibitor And Individual Amino Acid Residues Were Calculated. The Alkyl Spacer Is Located In A Cleft Along Helix 6 Of Mgmt. With Increasing Spacer Length There Is Increasing Interaction With Several Amino Acid Residues Which Play An Important Role In The Proposed Nucleotide Flipping Mechanism Required For Dna Repair.
    Doi:10.1021/jm010006E

    海关参考信息

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Ugur HC, Taspinar M, Ilgaz S, Sert F, Canpinar H, Rey JA, Castresana JS, Sunguroglu A. Chemotherapeutic resistance in anaplastic astrocytoma cell lines treated with a temozolomide-lomeguatrib combination. Mol Biol Rep. 2014 Feb;41(2):697-703. doi: 10.1007/s11033-013-2908-5. Epub 2013 Dec 25. doi: 10.1007/s13277-013-0738-7. Epub 2013 Mar 22. doi: 10.1038/bjc.2011.285. Epub 2011 Aug 2.
    4: Watson AJ, Sabharwal A, Thorncroft M, McGown G, Kerr R, Bojanic S, Soonawalla Z, King A, Miller A, Waller S, Leung H, Margison GP, Middleton MR. Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib. Clin Cancer Res. 2010 Jan 15;16(2):743-9. doi: 10.1158/1078-0432.CCR-09-1389. Epub 2010 Jan 12.
    5: Sabharwal A, Corrie PG, Midgley RS, Palmer C, Brady J, Mortimer P, Watson AJ, Margison GP, Middleton MR. A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer. Cancer Chemother Pharmacol. 2010 Oct;66(5):829-35. doi: 10.1007/s00280-009-1225-0. Epub 2009 Dec 29. doi: 10.1038/sj.bjc.6605015.

    合成参考文献


    参考文献:10.1002/ijc.10532
    摘要:Middleton MR, Thatcher N, McMurry TBH, McElhinney RS, Donnelly DJ, Margison GP. Effect of O6‐(4‐bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model. Intl Journal of Cancer. 2002 Jul 17;100(5):615–7. doi: 10.1002/ijc.10532.
    参考文献:10.1007/s00105-006-1195-7
    摘要:Rass K, Tadler D, Tilgen W. [Therapy of malignant melanoma. First-, second- and pathogenesis-oriented third-line therapies]. Hautarzt. 2006 Sep;57(9):773–84. doi: 10.1007/s00105-006-1195-7.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知